Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Randomized, Active Comparator-controlled, Clinical Trial to Study the Efficacy and Safety of the INtegral Cognitive REMediation Program (INCREM) in Patients with Depression

NCT06590025 is registered in ClinicalTrials.gov with Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau as lead sponsor.

NCT NCT06590025
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06590025 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Randomized, Active Comparator-controlled, Clinical Trial to Study the Efficacy and Safety of the INtegral Cognitive REMediation Program (INCREM) in Patients with Depression
Lead sponsor
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Phase
Phase 3
Overall status
Recruiting
Start date
September 13, 2023
Completion date
December 31, 2025
Enrollment
296 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

depression, depressive disorder